Eric Lefkofksy and Tempus Labs Use Biotechnology and Machine Learning for Precision Medicine

Eric Lefkofksy and Tempus Labs Use Biotechnology and Machine Learning for Precision Medicine

Brian Harris of Release Fact recently published the article, “Eric Lefkofksy’s Tempus Labs Uses Big Data Analytics to Revolutionize Cancer Medicine”. The article discusses the advances of Tempus Labs, a biotechnology health company started in 2015. The health tech start-up collaborated with national cancer centers and research universities across the country to create one of the largest libraries of data on cancer.

The library, along with the use of genome sequencing, allows doctors to create precision treatment methods for individual patients based on their biochemistry. By creating both a DNA and RNA sequencing of the tumor, the doctor is able to recognize the immune system characteristics of each tumor, allowing them to perceive which medicine is likely to work the best for each patient.

Tempus Labs also uses machine learning to integrate the different layers of information, creating a unified electronic medical record, complete with medical and pathology imaging.

In the three years since its inception, Tempus Labs has quickly become one of the top biotechnology companies in the health startup world. It has even been featured on Dr. Eric Topol’s yearly list of revolutionary medical technology.

The company has recently had a variety of groundbreaking technologies. One example that has recently been approved by the FDA is the gene therapy and editing. The technology is used to identify key genes that are mutated, causing vision impairment and even blindness. By targeting the mutation, the technology proposes to treat diseases like Hunter syndrome, previously thought to be untreatable.

It also uses pathogen sequencing to quickly sequence pathogen genomes. This may become imperative in quick public health responses to pathogen outbreaks.

It also has created a variety of technologies that use machine learning and AI to identify issues like skin cancer or eye diseases. The algorithm designed to identify skin lesions matches the ability of current physicians. The algorithm designed for eye diseases is even more accurate than a doctor’s. It is based on a library of retinal images that can help screen patients for diseases like diabetic retinopathy.

Eric Lefkofksy is one of Chicago’s leading entrepreneurs. He co-founded a variety of companies like Groupon and Lightbank. However, he is also a dedicated philanthropist, creating the Lefkofsky Family Foundation with his wife to aid high impact initiatives in medicine, human rights, and education.

Learn More: lefkofskyfoundation.com/